Pajjiż: Ingilterra
Lingwa: Ingliż
Sors: MHRA (Medicines & Healthcare Products Regulatory Agency)
Phenylephrine hydrochloride; Ibuprofen
Reckitt Benckiser Healthcare (UK) Ltd
Phenylephrine hydrochloride; Ibuprofen
5mg ; 200mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 03100000; GTIN: 5000158106253
CUSTOMER INFO: Minimum Point Size = 9.50pt N/A N/A N/A N/A N/A N/A N/A N/A BARCODE INFO BARCODE TYPE: BARCODE NUMBER: MAGNIFICATION: TRUNCATED BY: FULL HEIGHT: BAR HEIGHT (SMALLEST BAR) : BWR: ENCODED DATA: TRIDENT REFERENCE NO: ZEN REF: ACTION: BRAND: CATEGORY: SEGMENT GROUP: SEGMENT: PACK SIZE: MARKET/COUNTRY: DATE: COMPONENT CODE (2D IF APPLICABLE) : PARENT TECHNICAL PACKAGING SPECIFICATION: FINISHED GOODS CODE: SUPPLY POINT: PHARMACODE NO/NE: EDGEMARK POSITION: CAD CAM REF: PRINTER: SUBSTRATE: N/A RB Nottingham N/A 00000000 Nurofen Adult Cold & Flu Ibuprofen & Pseudoephedrine 12 / 16Tablets RB313180 PLEASE NOTE THAT ANY LOW RESOLUTION PAPER CANON COLOUR COPIES ASSOCIATED WITH THIS JOB SHOULD BE REFERRED TO FOR CONTENT, LAYOUT AND COLOUR SEPARATION ONLY. STUDIO USE ONLY V2.0 SM•ART CHECK RESULTS: CUTTER GUIDES TECHNICAL & NON PRINTING ITEMS CUTTER 2 (IF APPLICABLE) GUIDES 2 (IF APPLICABLE) Generic RB N-Lft-FB-D0069114-296x192-Lge-Reel TR1361406 Paper White UK 01/05/18 C JAMIE BROWN 00000000 G=2; O=0; R=0; - JB - 01/05/18 10:35:37 RB ARTWORK AND PRINT SPECIFICATION Connaught House, Connaught Road, Kingswood Business Park, Hull, HU7 3AP, England. T: +44 (0) 1482 828100 D0069114 ARTWORK TYPE: IDM SUBMISSION 10 mm 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 1 LTH PROCESS BLACK COLOURS (LEAFLET) RBH CONTACT: Mathilde Capart 00000000 00000000 00000000 N/A SINUS & BLOCKED NOSE 200MG/5MG TABLETS Contain ibuprofen and phenylephrine hydrochloride INFORMATION FOR THE USER Read all of this leaflet carefully because it contains important information for you. This medicine is available without prescription. However, you still need to use Nurofen Sinus & Blocked Nose 200mg/5mg Tablets carefully to get the best results from it. Keep this leaflet. You may want to read it again. If you have any further questions after you have read it, ask your doctor or pharmacist. YOU MUST CONTACT A DOCTOR IF YOUR SYMPTOMS WORSEN OR DO NOT IMPROVE AFTER 10 DAYS. If any side effects get serious, or Aqra d-dokument sħiħ
OBJECT 1 NUROFEN SINUS & BLOCKED NOSE 200MG/5MG TABLETS Summary of Product Characteristics Updated 23-May-2018 | Reckitt Benckiser Healthcare (UK) Ltd 1. Name of the medicinal product Nurofen Sinus & Blocked Nose 200mg/5mg Tablets 2. Qualitative and quantitative composition ACTIVE INGREDIENTS Ibuprofen Phenylephrine hydrochloride QUANTITY 200.0mg 5.0mg For full list of excipients, see Section 6.1 3. Pharmaceutical form Yellow film coated tablet, printed with an identifying motif (IPE) in black ink 4. Clinical particulars 4.1 Therapeutic indications For the relief of symptoms of cold and 'flu with associated congestion, including aches and pains, headache, fever, sore throat, blocked nose and sinuses. 4.2 Posology and method of administration For oral administration and short-term use only. ADULTS, THE ELDERLY AND CHILDREN OVER 12 YEARS: Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). The patient should consult a doctor if symptoms persist or worsen, or if the product is required for more than 10 days. Two tablets every 8 hours. Leave at least 4 hours between doses and do not exceed six tablets in any 24 hour period. NOT TO BE GIVEN TO CHILDREN UNDER 12 YEARS. 4.3 Contraindications Hypersensitivity to ibuprofen, phenylephrine or any of the excipients in the product. Hypertension and severe coronary heart disease. Patients who have previously shown hypersensitivity reactions (e.g. asthma, rhinitis, angioedema or urticaria) in response to aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs). Active or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes or proven ulceration or bleeding). History of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy. Severe heart failure (NYHA Class IV), renal failure or hepatic failure (see Section 4.4). Last trimester of pregnancy. Use with concomitant NSAIDs including cyclo-oxygenase-2 specific inhibitors (see Section 4.5). Aqra d-dokument sħiħ